Immunogenicity: 3 Consecutive Lots of GSK Bios' HPV-16/18 Vaccine Admnd Intramuscularly at 0,1,6 Mth Schedule in Healthy Females Aged 10-25 y & Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Demonstration of lot-to-lot consistency in terms of immunogenicity of 3 lots of HPV-16/18 vaccine.
GSK Clinical Trials
Denmark: The Danish National Committee on Biomedical Research Ethics